Floatz logo

(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine

Prostate Neoplasm

Nuvation Bio Inc.Small moleculePhase 1/2Active
C
32/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Prostate Neoplasm cohort.

Asset / SponsorPhaseRating
Docetaxel
Merck Sharp & Dohme LLC
Phase 4BBB
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 3BBB
LEUPROLIDE
Dana-Farber Cancer Institute
Phase 4BB
Abiraterone Acetate
Qilu Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine is also rated in:

breast carcinomaDormant
C
Indicative ·
32 / 100
View asset →
breast neoplasmDormant
C
Indicative ·
32 / 100
View asset →
prostate carcinomaDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →